{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:38Z","timestamp":1791357458767,"version":"4.3.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1675,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1124\/jpet.119.264515","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:40:31Z","timestamp":1584146431000},"page":"438-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pharmacological Profile of Naldemedine, a Peripherally Acting \u03bc-Opioid Receptor Antagonist: Comparison with Naloxone and Naloxegol"],"prefix":"10.1016","volume":"373","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8903-8245","authenticated-orcid":false,"given":"Toshiyuki","family":"Kanemasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohko","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.264515_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5055\/jom.2009.0014","article-title":"Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey","volume":"5","author":"Bell","year":"2009","journal-title":"J Opioid Manag"},{"issue":"2 Suppl","key":"10.1124\/jpet.119.264515_bib2","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"10.1124\/jpet.119.264515_bib3","first-page":"289","article-title":"Clinical utility of naloxegol in the treatment of opioid-induced constipation","volume":"8","author":"Bruner","year":"2015","journal-title":"J Pain Res"},{"key":"10.1124\/jpet.119.264515_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American gastroenterological association institute guideline on the medical management of opioid-induced constipation","volume":"156","author":"Crockett","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.264515_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/jpet.116.239061","article-title":"Pharmacologic profile of Naloxegol, a peripherally acting \u00b5-opioid receptor antagonist, for the treatment of opioid-induced constipation","volume":"361","author":"Floettmann","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264515_bib6","unstructured":"Hale M and Ko M (2019) Efficacy and safety of Naldemedine for opioid-induced constipation in patients with chronic non-cancer pain: subgroup analyses by opioid dose, #77 in Pain Week; 2019 September."},{"key":"10.1124\/jpet.119.264515_bib7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"Hale","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1124\/jpet.119.264515_bibib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bmcl.2018.11.007","article-title":"Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects","volume":"29","author":"Inagaki","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.119.264515_bib8","first-page":"67","article-title":"Schild\u2019s equation and the best estimate of pA2 value and dissociation constant of an antagonist","volume":"40","author":"Jankovi\u0107","year":"1999","journal-title":"Croat Med J"},{"key":"10.1124\/jpet.119.264515_bib9","doi-asserted-by":"crossref","first-page":"e13563","DOI":"10.1111\/nmo.13563","article-title":"Pharmacologic effects of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation","volume":"31","author":"Kanemasa","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"10.1124\/jpet.119.264515_bib10","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.119.264515_bib11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejphar.2015.12.033","article-title":"Differences in the morphine-induced inhibition of small and large intestinal transit: involvement of central and peripheral \u03bc-opioid receptors in mice","volume":"771","author":"Matsumoto","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264515_bib12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/papr.12646","article-title":"Oral prolonged-release oxycodone\/naloxone for managing pain and opioid-induced constipation: a review of the evidence","volume":"18","author":"Morlion","year":"2018","journal-title":"Pain Pract"},{"key":"10.1124\/jpet.119.264515_bib13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1476-5381.2011.01390.x","article-title":"Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo","volume":"164","author":"Ramsey","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.264515_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JPR.S175900","article-title":"Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label phase III studies","volume":"12","author":"Saito","year":"2018","journal-title":"J Pain Res"},{"key":"10.1124\/jpet.119.264515_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice","volume":"38","author":"Sigmon","year":"2012","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1124\/jpet.119.264515_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.lfs.2018.07.028","article-title":"Pharmacological profile of TAN-452, a novel peripherally acting opioid receptor antagonist for the treatment of opioid-induced bowel syndromes","volume":"215","author":"Suzuki","year":"2018","journal-title":"Life Sci"},{"key":"10.1124\/jpet.119.264515_bib17","first-page":"1347","article-title":"Management of common opioid-induced adverse effects","volume":"74","author":"Swegle","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1124\/jpet.119.264515_bib18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrd1500","article-title":"Biochemical mechanisms of drug action: what does it take for success?","volume":"3","author":"Swinney","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.119.264515_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.dmpk.2018.12.002","article-title":"Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist","volume":"34","author":"Watari","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/jpet.119.264515_bib20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/j.pain.0000000000001174","article-title":"Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study","volume":"159","author":"Webster","year":"2018","journal-title":"Pain"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652425895X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652425895X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.264515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:56:50Z","timestamp":1739973410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652425895X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S002235652425895X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.264515","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Profile of Naldemedine, a Peripherally Acting \u03bc-Opioid Receptor Antagonist: Comparison with Naloxone and Naloxegol","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.264515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s)","name":"copyright","label":"Copyright"}]}}